Ricky Goldwasser
Stock Analyst at Morgan Stanley
(3.32)
# 1,051
Out of 5,124 analysts
230
Total ratings
62.89%
Success rate
9.33%
Average return
Main Sectors:
Stocks Rated by Ricky Goldwasser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DOCS Doximity | Upgrades: Overweight | $62 → $65 | $44.28 | +46.79% | 11 | Dec 15, 2025 | |
| CRL Charles River Laboratories International | Maintains: Equal-Weight | $170 → $185 | $199.48 | -7.26% | 23 | Nov 11, 2025 | |
| CNC Centene | Maintains: Equal-Weight | $28 → $38 | $41.15 | -7.65% | 14 | Oct 14, 2025 | |
| UNH UnitedHealth Group | Maintains: Overweight | $325 → $395 | $330.11 | +19.66% | 20 | Sep 12, 2025 | |
| LH Labcorp Holdings | Maintains: Overweight | $283 → $306 | $250.88 | +21.97% | 17 | Jul 25, 2025 | |
| LFST LifeStance Health Group | Reiterates: Overweight | $10 | $7.04 | +42.05% | 8 | Apr 22, 2024 | |
| GDRX GoodRx Holdings | Maintains: Equal-Weight | $8 → $5.5 | $2.71 | +102.95% | 9 | Nov 10, 2023 | |
| OSCR Oscar Health | Maintains: Equal-Weight | $5 → $7.5 | $14.37 | -47.81% | 6 | Aug 30, 2023 | |
| ALHC Alignment Healthcare | Maintains: Overweight | $19 → $12 | $19.75 | -39.24% | 8 | Aug 30, 2023 | |
| DGX Quest Diagnostics | Reiterates: Equal-Weight | $145 | $173.53 | -16.44% | 17 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $365 | $173.54 | +110.33% | 7 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $403 → $420 | $820.29 | -48.80% | 27 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $120 | $4.91 | +2,343.99% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $549 → $620 | $256.13 | +142.06% | 11 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $485 → $500 | $350.55 | +42.63% | 2 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $124 | $79.36 | +56.25% | 9 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $296 → $318 | $275.23 | +15.54% | 11 | Aug 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $70 | $205.50 | -65.94% | 17 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $182 → $195 | $225.41 | -13.49% | 6 | Oct 21, 2020 |
Doximity
Dec 15, 2025
Upgrades: Overweight
Price Target: $62 → $65
Current: $44.28
Upside: +46.79%
Charles River Laboratories International
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $170 → $185
Current: $199.48
Upside: -7.26%
Centene
Oct 14, 2025
Maintains: Equal-Weight
Price Target: $28 → $38
Current: $41.15
Upside: -7.65%
UnitedHealth Group
Sep 12, 2025
Maintains: Overweight
Price Target: $325 → $395
Current: $330.11
Upside: +19.66%
Labcorp Holdings
Jul 25, 2025
Maintains: Overweight
Price Target: $283 → $306
Current: $250.88
Upside: +21.97%
LifeStance Health Group
Apr 22, 2024
Reiterates: Overweight
Price Target: $10
Current: $7.04
Upside: +42.05%
GoodRx Holdings
Nov 10, 2023
Maintains: Equal-Weight
Price Target: $8 → $5.5
Current: $2.71
Upside: +102.95%
Oscar Health
Aug 30, 2023
Maintains: Equal-Weight
Price Target: $5 → $7.5
Current: $14.37
Upside: -47.81%
Alignment Healthcare
Aug 30, 2023
Maintains: Overweight
Price Target: $19 → $12
Current: $19.75
Upside: -39.24%
Quest Diagnostics
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $145
Current: $173.53
Upside: -16.44%
Jul 14, 2023
Reiterates: Overweight
Price Target: $365
Current: $173.54
Upside: +110.33%
Jan 6, 2023
Maintains: Overweight
Price Target: $403 → $420
Current: $820.29
Upside: -48.80%
Jan 6, 2023
Maintains: Overweight
Price Target: $140 → $120
Current: $4.91
Upside: +2,343.99%
Oct 31, 2022
Maintains: Overweight
Price Target: $549 → $620
Current: $256.13
Upside: +142.06%
Oct 21, 2022
Maintains: Equal-Weight
Price Target: $485 → $500
Current: $350.55
Upside: +42.63%
Oct 11, 2022
Maintains: Overweight
Price Target: $127 → $124
Current: $79.36
Upside: +56.25%
Aug 17, 2022
Maintains: Overweight
Price Target: $296 → $318
Current: $275.23
Upside: +15.54%
Jul 14, 2022
Maintains: Overweight
Price Target: $74 → $70
Current: $205.50
Upside: -65.94%
Oct 21, 2020
Maintains: Overweight
Price Target: $182 → $195
Current: $225.41
Upside: -13.49%